Equity Profile

REGN

Regeneron Pharmaceuticals, Inc.

Health CareBiotechnology$69.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and drive future profits.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases. As a key player in the health care sector, Regeneron is known for its innovative treatments and research in areas like eye diseases, cancer, and inflammatory conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q1-2026, Regeneron reported an impressive EPS of $9.47, significantly beating estimates by over 50%. However, the stock reacted negatively, dropping 6.21% the following day.

Management Promises & Guidance

Focus on expanding the product pipeline.
Commitment to maintaining strong financial performance.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Overall, expectations are mixed heading into the earnings report, with investors looking for continued strong performance but wary of potential market volatility.

Bull Case

If Regeneron continues its trend of beating EPS estimates, it could signal robust growth and innovation, leading to a positive stock reaction.

Bear Case

Conversely, any signs of slowing revenue growth or issues in the product pipeline could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Given the company's history of beating EPS estimates, this number will be crucial for determining market sentiment.

What updates can be provided on the product pipeline?

Insights into the product pipeline will help investors gauge future growth potential and revenue streams.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regeneron's ability to continue its strong EPS performance, given its historical track record of beating estimates.

Supporting Evidence

Regeneron has consistently exceeded EPS expectations in the past quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a significant surprise.

Insider buying activity may signal confidence in the company's future performance.

Key Risk

If EPS comes in below $8.00, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can sustain its impressive growth trajectory amid increasing competition and market pressures.

Bull Confirmed If

An EPS of $10.00 or higher would confirm strong financial health and growth potential.

Bear Confirmed If

An EPS below $8.00 could indicate underlying issues and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±13.18%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could see an average one-day move of +11.82%, confirming strong growth.

In-Line / Cautious

If results are in line with expectations, the stock may react modestly, reflecting cautious sentiment among investors.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of -6.87%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch dates.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations.
4Insights into cost management strategies and their impact on margins.
5Any commentary on competitive pressures in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and drive future profits.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

REGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+42.98%

Avg Stock Reaction

-0.40%

Last Quarter Recap

In Q1-2026, Regeneron reported an impressive EPS of $9.47, significantly beating estimates by over 50%. However, the stock reacted negatively, dropping 6.21% the following day.

Management Promises & Guidance

Focus on expanding the product pipeline.
Commitment to maintaining strong financial performance.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Overall, expectations are mixed heading into the earnings report, with investors looking for continued strong performance but wary of potential market volatility.

Bull Case

If Regeneron continues its trend of beating EPS estimates, it could signal robust growth and innovation, leading to a positive stock reaction.

Bear Case

Conversely, any signs of slowing revenue growth or issues in the product pipeline could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Given the company's history of beating EPS estimates, this number will be crucial for determining market sentiment.

What updates can be provided on the product pipeline?

Insights into the product pipeline will help investors gauge future growth potential and revenue streams.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Regeneron's ability to continue its strong EPS performance, given its historical track record of beating estimates.

Supporting Evidence

Regeneron has consistently exceeded EPS expectations in the past quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a significant surprise.

Insider buying activity may signal confidence in the company's future performance.

Key Risk

If EPS comes in below $8.00, it could undermine the bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Regeneron can sustain its impressive growth trajectory amid increasing competition and market pressures.

Bull Confirmed If

An EPS of $10.00 or higher would confirm strong financial health and growth potential.

Bear Confirmed If

An EPS below $8.00 could indicate underlying issues and lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±13.18%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.2% while REGN has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.1%

Calls (71K)P/C Ratio: 0.36Puts (80K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regeneron beats expectations, history suggests the stock could see an average one-day move of +11.82%, confirming strong growth.

In-Line / Cautious

If results are in line with expectations, the stock may react modestly, reflecting cautious sentiment among investors.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of -6.87%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-LAJulia LetlowRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch dates.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations.
4Insights into cost management strategies and their impact on margins.
5Any commentary on competitive pressures in the biotechnology space.